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Introduction: Evidence-based interventions are needed to treat burn wound infection (BWI). 
Evidence syntheses have been limited by heterogeneity of indicators used to report BWI across 
trials. Consistent reporting of BWI would be facilitated by an agreed minimum set of indicators. The 
Infection Consensus in Burns study aimed to achieve expert consensus about a Core Indicator Set 
(CIS) for BWI. 
Methods: The CIS was established through development of a long-list of BWI indicators identified 
from a systematic review and expert input. In a Delphi survey, UK expert participants rated the 
indicators according to use in everyday practice, importance for diagnosis and frequency of 
observation in patients with BWI. Indicators were included in the CIS if >75% of participants agreed it 
was important for diagnosis and used in everyday practice, and >50% rated it as frequently observed 
in patients with BWI.  
Results: 195 indicators were identified from the systematic review and reduced to 29 survey items 
through merging of items with the same meaning. Seventy-five UK experts participated in the Delphi 
survey. Following a single survey round and a consensus meeting with an expert panel, four items 
were included in the CIS: pyrexia, spreading erythema, change in white cell count, and presence of 
pathogenic microbes. 
Discussion and conclusions: To facilitate evidence synthesis, a single country systematic, expert-
informed approach was taken to develop a core set of indicators (CIS) to be reported consistently 
across trials reporting BWI as an outcome. Future work requires verification of the CIS with 





Research studies suggest that 10-20% of people with burns develop a burn wound infection 
(BWI).[1-3] BWI delays healing, increases risks of scarring, and sepsis if untreated. These will increase 
length of hospital stay, number of operative events and healthcare costs.[4, 5] In patients with burns 
larger than 40% total body surface area, infection has been causally associated with 75% of 
deaths.[2, 6] Interventions for BWI are needed to improve patient outcomes and decrease 
healthcare costs. 
To select interventions for BWI to achieve optimal patient outcomes, evidence is needed from high-
quality RCTs, aggregated in systematic reviews.[7] Evidence synthesis can be adversely impacted by 
varying definitions of a single outcome across trials. This heterogeneity can cause differing 
estimations of the effects of the same intervention across studies, and is common.[8, 9] In a review 
of surgical site infection, 41 differing definitions were identified across 90 studies.[10] In a review 
investigating oesophagectomy outcomes, 22 different definitions of anastomotic leak were reported 
across 28 studies[11].  Cochrane burn care reviews report that varying definitions of BWI have 
prevented accurate assessment of intervention effectiveness across trials.[12, 13] In a systematic 
review of BWI definitions, 27 different indicators of BWI were reported across 41 studies.[14]  
One reason for this heterogeneity is the lack of an objective reference standard for clinical diagnosis 
of BWI. Diagnosis is based on clinician judgement, informed by indicators of BWI, comprising 
patient-reported symptoms, clinician-observed signs and non-specific laboratory tests to detect 
systemic inflammation, as well as presence of bacteria in the wound. However, presence of bacteria 
in the wound is correlated with, but not diagnostic of, clinical infection and may simply represent 
wound colonisation.[15, 16] To address this difficulty with BWI diagnosis, consensus criteria have 
been developed from the American Burn Association (ABA)[17], Centre for Disease Control 
(CDC)[18], and European Wound Management Association(EWMA)[19]. However, these criteria are 
infrequently used in research and have clinical limitations.[14] Numerous indicators are included in 
these criteria, which complicates diagnosis and reporting. There is also the mandated use of wound 
biopsies in ABA and CDC criteria.[17, 18] Wound biopsy is invasive, increases risk of infection and 
scarring[20], and is not used in all countries. Wound swabs are the primary means to determine 
presence of bacteria in the wound.[21] The EWMA consensus criteria[19] prioritise use of indicators 
that are rarely seen (e.g. Ecthyma Gangrenosum). Furthermore, the EWMA consensus criteria do not 
include patient-reported symptoms of BWI.  
To achieve consistent reporting of BWI across trials, consensus is needed about a minimum set of 




important as important to BWI diagnosis, frequently observed in patients, and commonly used to 
diagnose BWI in clinical practice. To ensure relevance and uptake by researchers, the selected 
indicators should address the above-described limitations of the described consensus criteria. A CIS 
will provide a minimum dataset to standardise reporting about BWI in trials reporting this outcome 
without limiting the reporting of other indictors. This will reduce clinical heterogeneity between 
studies, facilitating more efficient evidence synthesis, and enabling faster identification of effective 
treatments for patients.  
The aim of the Infection Consensus in Burns Study (ICon-B), is to agree a CIS for BWI.  The ICon-B 
study represents the first stage, undertaken in the UK, of an international effort to agree a CIS.   
 
METHOD 
The objectives of the ICon-B study are to: 
• Establish a long-list of candidate clinical indicators for reporting BWI (Stage 1). 
• Conduct a Delphi survey with UK BWI experts to achieve consensus in indicator prioritisation 
(Stage 2).  
• Select the final CIS for reporting BWI based on the results of the Delphi survey and agreement 
between the ICon-B expert panel (Stage 3).  
Protocol: The protocol for this study was registered on the PROSPERO database and is published 
(Reference CRD42018096647).[22] Changes to this protocol are justified in this paper. 
Scope: The CIS will be applicable to reporting BWI outcomes in clinical trials involving patients of any 
age with acute (before healing) burn wounds of any size and aetiology, in in- and out-patient 
settings. It is not designed for use in trials reporting sepsis secondary to burns.  
Study expert panel: The panel comprised 14 health care professionals (HCPs) and researchers expert 
in BWI, including burn surgeons (BD, DC, SF, MS, RA), clinical microbiologists (LT, LM), academics in 
burn research (AD, AY, JD), burns research nurses (KC, SB, KM), and a biochemist (ATAJ).  
Patient and public involvement: Patients were not involved in this first stage study. While patients 
can report symptoms of BWI, they are not involved in interpreting clinician-observed signs and tests. 
Therefore, it would be unreasonable to expect patients to prioritise BWI indicators in a Delphi 
survey. Patients will be involved in a future international study to support clarification of definitions 




Stage 1: Establishing the long list of BWI candidate clinical indicators 
We define clinical indicators as: 
• Patient-reported symptoms (e.g. change in wound appearance, increased pain). 
• Clinician-observed signs (e.g. spreading erythema, pyrexia, purulent exudate). 
• Laboratory tests for systemic inflammation (e.g. white blood cell count, C-Reactive Protein) and 
the presence of microbes in the wound (bacteria from wound swab or biopsy).  
Systematic review (SR):  
Candidate clinical indicators for the Delphi survey were identified from a systematic review of 
randomised controlled trials and observational studies of interventions reporting a BWI 
outcome.[14] An electronic search of four databases (Ovid MEDLINE, Ovid Embase, Cinahl, Cochrane 
Register of Trials) was conducted. Inclusion criteria were: 
• Published January 2010-November 2016 
• Full-text article  
• Reporting an observational study or randomised controlled trial 
• Reporting data on acute burn wound injuries. 
• Written in English. 
• Carried out in a clinical setting. 
• Reporting BWI as an outcome and not wound colonisation alone. 
• A human study.  
Additional consensus criteria/ BWI definitions: The study expert panel were asked to identify 
additional articles describing indicators to define BWI.  
Screening: Identified studies were systematically screened using the inclusion criteria, in two stages 
(abstract, title and then full text) by one researcher, with a second researcher screening 20% of 
studies. Disagreements were resolved via discussion, with a third reviewer where needed.  
Data extraction: The indicators used to define BWI were extracted verbatim from studies. Where 
consensus criteria or another author’s definition of BWI was cited, we accessed the primary study 
and extracted the indicators directly.  The following data were recorded in a MS Excel spreadsheet: 
• Study identifiers (author name, date of publication).  
• Indicators used to define BWI, extracted verbatim from methods/ results.  





Identifying unique indicators to inform survey items: 
Following extraction, one researcher (AD) carried out preliminary de-duplication, sorting indicators 
with the same/similar meaning into groups where the similar terminology had been used (e.g. 
‘presence of microbes’ and ‘presence of pathogens’ in the wound). Similar indicators using differing 
terminology, or that were unclear in their meaning, were organised as separate groupings for review 
(e.g. ‘rapid associated change in burn wound appearance or character’, and ‘unfavourable and 
unexpected local evolution’). 
The expert panel met to review the long list and to confirm or reject the decisions about potential 
duplicates and potentially redundant indicators (e.g. those relating to sepsis only). A unique 
definition of each indicator was agreed through iterative discussion.  
 
Stage 2: Delphi Survey of infection indicators 
The Delphi technique was selected to gather data from a range of stakeholders.[23] A Delphi survey 
to achieve expert consensus is recommended by the Core Outcome Measures in Effectiveness Trials 
(COMET) group for development of Core Outcome Sets (COS)[24]. Delphi surveys have been 
successfully used to develop criteria for a clinical diagnostic tool for hepatic and renal cyst infection 
[25] and for diagnosis of paediatric joint or bone infection[26]. Delphi surveys use iterative 
questionnaire rounds, between which data are summarised. The responses are anonymously fed 
back to stakeholders within any subsequent rounds to enable consensus. The anonymity of Delphi 
surveys may facilitate gathering of more truthful views from respondents,[27] and can be 
administered electronically to gather opinions of a larger number of stakeholders than can be 
achieved face-to-face.  
 
Ethics  
No ethical approval for the Delphi survey was required, as the research was conducted outside the 
NHS.  
 
Delphi sample size 
There are no guidelines to determine the number of participants needed for a Delphi Survey. The 




generalisation of findings[24]. We aimed to achieve representation from multi-disciplinary BWI 
experts from all four UK countries and as many burns services as possible.  
Participants 
Stakeholders were invited to take part if they were UK-based HCPs in burn care and diagnosis of BWI 
from the following groups:  
• Consultant plastic/burn surgeons. 
• Trainee plastic surgeons with at least three consecutive months’ burn care experience. 
• Burn care and research nurses with at least three consecutive months’ burn care experience. 
• Clinical microbiologists involved in BWI diagnosis, working in a hospital with a burns service. 
• General practitioners who had seen at least one suspected BWI in the preceding month. 
• Emergency department staff who had seen at least one suspected BWI in the preceding 
month. 
• Intensivists/anaesthetists working in burn care.  
 
Participants were approached by email through professional organisations: British Burn Association 
(BBA), Care of Burns in Scotland (COBIS), the Faculty of Intensive Care Medicine and the National 
Academic Mailing List service (JISC Burns Research). Twitter and personalised emails to contacts of 
the expert panel in all four UK countries were used.   
 
Survey items 
The Delphi survey comprised demographics questions and BWI indicator items: 
i. Demographic questions:  
• Job role,  
• Patient group worked with (adults, children, both). 
• UK country and burns service. 
 
ii. BWI indicators:  
Each candidate clinical indicator, referred to as a survey ‘item’ was assigned to patient-reported 
symptoms, clinical signs or laboratory tests. For each item, three questions were asked with the 
following response scales:  




Participants recorded their response by selecting ‘yes’ or ‘no’.  
 
2. How important is this indicator in diagnosing burn wound infection in your everyday practice? 
Participants recorded their response on a Likert-type scale with text anchors, ranging from 1 to 9, 
where 1-3 indicated ‘not at all important’, 4-6 indicated ‘important but not vital’ and 7-9 indicated 
‘very important’.  
 
2. How frequently do you see this symptom/sign in patients you diagnose with burn wound infection? 
Participants recorded their response on a Likert-type scale with text anchors, ranging from 1 to 9, 
where 1 indicated ‘very infrequently’ and 9 indicated ‘very frequently’.   
For each question participants could state they did not have an opinion about the indicator (0).  
 
Survey piloting:  
The survey was piloted in the UH Bristol NHS Foundation Trust burns service, emergency 
department and clinical microbiology team. Participants recorded whether they understood the 
survey purpose, the completion instructions, whether questions were unclear, and if they had 
additional indicators to include. Feedback revealed that some participants had misunderstood the 
survey purpose; that they believed it aimed to develop a diagnostic tool. This informed the 
participant information at the start of the survey.   
Following piloting, an online survey was developed in REDCap (Research Electronic Data Capture [28, 
29]. The survey URL was distributed by email, using the mailing lists and of the above described 
organisations and the expert panel’s contacts.  
 
Data extraction and analysis: 
Any individual who completed the consent form, provided their email address, and provided a 
response to at least one survey item, was considered a survey participant. Any completed datapoint 
was included in the dataset to maximise data available for analysis. For each item, descriptive data 
were produced:   




• Number and percentage of participants indicating ‘0’ (no opinion). 
• Number and percentage of participants rating the items ‘yes’ and ‘no’, where applicable 
(question 1), and 1-3, 4-6 or 7-9 for the Likert-type scales (questions 2 and 3). 
Data were tabulated for each item, excluding 0 responses (no opinion). Percentages for the number 
of participants rating the item as ‘yes’ or ‘no’ (question 1), and 1-3, 4-6 and 7-9 (questions 2 & 3) 
were calculated with the denominator being the number of participants who completed the item 
with a value above 0 (no opinion) i.e. 1-9, or yes/no.    
Dropping and modification of items between survey rounds: The threshold for items to be carried 
through to the second round and expert panel meeting were pre-specified.[22] Items were carried 
through to a second round of the survey if >75% of participants stated that they used the indicator 
to diagnose BWI as part of their everyday practice (question 1). If so, the item would be included in 
the next round if:  >75% of participants rated it as 7-9  on the importance scale and 7-9 on the  
frequency scale, with <15% rating it as unimportant/infrequently seen (1-3) on either scale.  
 
Stage 3: Consensus meeting with ICon-B expert panel 
After completion of the survey first round, the expert panel met to review the survey data and 
identify next steps.  
 
RESULTS 
Stage 1: Establishing a long list of BWI candidate indicators 
Systematic review  
Of 2,056 identified studies, 72 met the inclusion criteria. Of these, 44 described the indicators used 
to define BWI (see figure I).  
Six studies cited the use of a set of consensus criteria (ABA)[17], and two cited the use of another 
author’s definition of BWI.[30, 31] The expert panel recommended the inclusion of the EWMA[19] 
and CDC[18] consensus criteria.   
 




From the 44 studies, the three sets of consensus criteria and the two cited BWI definitions, 195 BWI 
indicators were extracted. Following initial de-duplication and grouping of the indicators undertaken 
by one researcher (AD), 75 groups of indicators were presented to the expert panel. These were 
iteratively reviewed for duplication and redundancy, resulting in 27 unique indicator items for the 
survey (Appendix A). Two additional items were added, as one indicator could be both patient-
reported and clinically observed (wound smell), and one indicator comprised two items (colour and 
volume of exudate).  
 
Stage 2: Delphi survey 
Demographic characteristics of participants 
Ninety-six participants viewed the survey, of which 75 (78%) completed at least one indicator item. 
The demographic characteristics of the participants are presented in table I.  
 
Ratings of BWI clinical indicators 
1. Use of the indicator in everyday practice 
Table II indicates participant ratings for the 29 survey items.  
Nine items met the pre-specified threshold for use of the indicator in everyday practice (>75% of 
participants indicating yes): high temperature, spreading erythema, clinician-observed wound smell, 
change in colour of exudate, wound or surrounding skin hot, change in C-Reactive Protein, change in 
white blood cell count, bacteria in blood, and potentially pathogenic microbes identified from 
wound swab.   
2. Importance of the indicator for diagnosing BWI 
Eight items met the pre-specified threshold for being very important (rated 7-9) for diagnosis of BWI 
by >75% of participants (Table II, second column). Three items were viewed as important for 
diagnosing BWI but were not used by >75% of participants in everyday practice for diagnosis. These 
were ascending lymphangitis, (no) signs of alternative infection, and invasion of bacteria through 
biopsy/tissue culture. Five items met the threshold for use of the indicator in everyday practice:  
high temperature, spreading erythema, change in white blood cell count, bacteria in the blood, 
potentially pathogenic microbes from wound swab  




No indicators met the pre-specified threshold for frequency of observation in patients diagnosed 
with BWI.  
Stage 3: Consensus meeting with ICon-B expert panel 
Following discussion, the expert panel agreed a variation to the study protocol. They agreed to 
reduce the threshold for carrying items through where > 50% of participants had rated that they 
observed the indicator very frequently (7-9) in patients with BWI.  
Eight indicators met this threshold: high temperature, change in C-Reactive Protein, change in white 
blood cell count, potentially pathogenic microbes from wound swab, patient feels unwell, spreading 
erythema, improvement in the patient’s condition following administration of antimicrobials, and 
wound smell.  Of these, only four also met the >75% threshold for use of the indicator in everyday 
practice, and importance of the indicator for diagnosing BWI. These were: high temperature, 
spreading erythema, white cell count, and potentially pathogenic microbes from the wound swab.  
In a further protocol variation, the expert panel agreed that a second round of the survey was not 
necessary in this stage one study. Applying the thresholds described above, there was consensus 
about only four items. These were:  
• Pyrexia 
• Spreading redness in unburned surrounding tissue (spreading erythema) 
• Change in white blood cell count (leucocytosis) 




The use of varying indicators to define BWI has hindered accurate conclusions being drawn about 
intervention effectiveness in Cochrane reviews.[12, 13] The aim of the ICon-B study was to agree a 
core set of the most important indicators of BWI, to support consistent reporting across clinical burn 
care trials and more effective evidence synthesis. Most important was defined as the indicator being 
a priority for diagnosis, used in everyday clinical practice and frequently seen in patients with BWI. 
Consensus was achieved for four clinical indicators: pyrexia, spreading erythema, change in white 
blood cell count, and potentially pathogenic microbes present in the wound (identified from wound 
swab). The CIS provides a minimum dataset to be reported across trials for BWI while allowing the 
reporting of other indictors relevant to the research question. It does not represent a definition of 
BWI or a clinical tool for diagnosis. The approach taken in this study is similar to that used by 




of all types.[32] The expert consensus methodology that we have used could be replicated to 
identify other core indicators to be reported for other outcomes for which no accepted standard is 
available. In burn care this may include wound healing, quality of life, or scarring, which are all 
multidimensional and informed by several indicators.[33-35]  
Previous consensus-informed standards to address heterogeneity in the indicators used to report 
BWI have not been adopted in routine practice or for research.[17-19] This is due to limitations 
including  the use of indicators that are not used to diagnose BWI in all patients, or in all countries 
(e.g. wound biopsy[17, 18]), and the incorporation of indicators rarely seen in patients with BWI (e.g. 
Ecthyma Gangrenosum[19]). We have addressed these by identifying indicators used in everyday 
practice and frequently seen in patients diagnosed with BWI. This will ensure that data collection can 
be undertaken as part of usual care. An unexpected finding was that no indicator was reported by at 
least 75% of participants as frequently observed in patients with BWI. This highlights the multiple 
signs and symptoms used in its clinical diagnosis.  Through agreement with the expert panel, a 
pragmatic approach was taken; the threshold for use in the CIS was agreed to be more than 50% of 
participants reporting that the indicator is seen frequently in patients with BWI.  
The strengths of this study are that we used a pre-defined protocol to identify the CIS and achieved 
representation from many disciplines involved in the diagnosis and treatment of patients with BWI. 
We have transparently reported two changes to the protocol. We achieved representation of 
participants from three of the four UK countries. Expansion to an international audience will be 
important, to ensure relevance and acceptability of the CIS to global researchers. It is possible that 
HCPs working in low resource settings may have differing views about which indicators are most 
important and differing resources available to conduct relevant tests. This issue can be addressed by 
asking global researchers whether indicators are used to inform diagnosis in daily practice.   
Limitations of this study are that only one Delphi survey round was conducted. This decision was 
reached through expert panel agreement that consensus had been achieved for four indicators 
within one round. We acknowledge that Delphi surveys typically involve more than one round, to 
enable feedback of participants’ responses to reach consensus. We anticipate that extending this 
survey to an international audience, where there may be greater variation in practices, will require a 
survey with two or more rounds to achieve consensus. 
Our study has identified a core set of indicators considered most important for reporting BWI 
outcomes with experts from UK burn services. If adopted by investigators, the CIS will improve the 
consistency with which BWI is reported across trials. This will reduce clinical heterogeneity and 




internationally. Other work will be undertaken to define metrics for the final chosen indicators. Two 
of the four CIS indicators (pyrexia and white cell count) are reported as numerical values. The 
presence of potentially pathogenic microbes is usually assessed quantitatively and/or qualitatively, 
and erythema is a clinical judgement.  
Conclusions: This study has taken a systematic approach to agreeing the most important indicators 
for reporting BWI consistently across trials. We have called this a CIS. If implemented, this CIS will 
reduce clinical heterogeneity between trials and support efficient evidence synthesis, to identify the 
most effective treatments and inform clinical decision-making for patients with burn injuries. Further 
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Figure 1: Flow diagram of process of survey item development 
 
  
46 studies reported indicators of BWI 
Expert Recommendation 
2 consensus criteria papers 
(EWMA; CDC) 
Verbatim indicator extraction 
n=195 indicators of BWI 
 
Grouping and identification of potential 
duplicates for expert panel review 
n=75 groups of BWI indicators  
 
Reduction of duplicate and redundant 
indicators through expert panel 
discussion 
n=27 indicators of BWI 
 
Definition of indicators as items for 
survey and assignment to categories 
29 survey items organised into:  
1. Patient reported symptoms (n=3) 
2. Clinician observed signs (n=18) 
3. Laboratory tests (n=8) 
 
Systematic review of BWI indicators 




Table I: Participant demographic characteristics 
Participant type N (%) 
(%) Consultant plastic surgeon 9 (12) 
12.0 Plastic surgery trainee 2 ( .7) 
 Clinical burns nurse 31 (41.3) 
41.3 Burns research nurse 5 (6.7) 
Clinical microbiologist / infectious diseases physician 
working in a hospital with a burns service 
4 (5.3) 
Emergency department doctor 5 (6.7) 
GP 1 (1.3) 
Intensive care doctor/ anaesthetist caring for patients 
with burns 
8 (10.7) 
Intensive care nurse caring for patients with burns 3 (4.0) 
Clinical research fellow 1 (1.3) 
Burns care advisor 1 (1.3) 
Burns clinic coordinator 1 (1.3)  
Burn ward matron 1 (1.3)  
Emergency burns assessment centre nurse 1 (1.3)  
Allied Health Professionals (OT, Physio) 2 (2.7) 
Country  
England 62 (82.7) 
Wales 8 (10.7) 
Scotland 4 (5.3) 
Northern Ireland 0 
USA* 1 (1.3) 
Patients worked with  
Adults only (>16 years of age) 23 (30.7) 
Children only (<16 years) 17 (22.7) 
Adults and children 35 (46.7) 





Table II: Item ratings for the first round of the Delphi survey  
Grey boxes indicate items reaching the inclusion threshold; bold items are those included in the CIS.  
Indicator  Participants stating 





9) for Importance 
of Indicator in 
diagnosis of BWI 
Participants rating 
very frequently (7-9) 
for frequency with 
which the indicator 
is observed in 
patients diagnosed 
with BWI 
 % (n)  % (n) % (n) 
Patient reported symptoms     
Patient feels unwell 74.6 (50) 65.3 (49) 53.5 (23) 
Wound pain 66.1 (41) 54.8 (40) 29.6 (21) 
Wound smell 65.1 (41) 47.3 (35) 36.1 (26) 
Clinician observed signs     
High temperature 87.3 (55) 81.2 (56) 70.6 (48) 
Low temperature 34.9 (22) 34.8(24) 2.9 (2) 
Low blood pressure 38.1 (24) 41.2 (28) 27.5 (19) 
Tachycardia 68.8 (44) 60.0 (42) 49.3 (34) 
Spreading erythema 91.2 (62) 88.6 (62) 58.0 (40) 
Ascending lymphangitis 72.3 (47) 82.1 (55) 25.8 (17) 
Improvement following use of 
antimicrobials 
62.1 (36) 59.1 (39) 51.6 (33) 
Signs of alternative infection 67.2 (39) 76.1 (51) 38.5 (25) 
Unexpected increase in burn depth 61.4 (35) 62.9 (39) 25.8 (16) 
Unexpected change in wound colour 49.2 (30) 42.2 (27) 20.3 (13) 
Wound smell 80.6 (50) 69.2 (45) 51.6 (33) 
(Change in) colour of exudate 75.0 (45) 62.7 (42) 43.1 (28) 
(Change in) volume of exudate 41.7 (25) 31.3 (20) 16.1 (10) 
Wound or surrounding skin hot 78.1 (50) 74.2 (49) 44.4 (28) 
Wound hardness 29.8 (17) 27.4 (17) 6.6 (4) 
Oedema  62.9 (39) 49.2 (32) 30.2 (19) 
Loss of skin graft/allograft 55.7 (34) 63.5 (40 27.9 (17) 
Loss of skin substitute 65.4 (34) 69.0 (40) 26.8 (15) 
Laboratory tests     
Change in C-Reactive Protein 79.3 (46) 72.1 (44) 60.0 (36) 
Change in Procalcitonin 12.1 (4) 28.0 (7) 4.8 (1) 
Change in blood glucose 53.5 (23) 53.1 (26) 41.7 (20) 
Change in white blood cell count 80.4 (41) 76.4 (42) 68.5 (37) 
Bacteria in blood 80.4 (41) 79.2 (42) 23.1 (12) 
Invasion of bacteria through 
biopsy/tissue culture 
68.0 (34) 83.0 (39) 32.5 (13) 
Microbes from wound swab 68.0 (24) 40.7 (24) 55.2 (32) 
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